4.7 Article

Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fbioe.2022.920766

关键词

mesoporous polydopamine; fibroblast activation protein; fibroblast activation protein inhibitor; pulmonary fibrosis; antifibrosis therapy

资金

  1. Department of Science and Technology of Guangzhou and Guangzhou Medical University
  2. National Natural Science Foundation of China [82001879]
  3. Applied and Basic Research Foundation of Guangdong Province [2020A1515110159]
  4. Science and Technology Project of Guangzhou City [202102010354]
  5. Zhongnanshan Medical Foundation of Guangdong Province [ZNSA-2020003]

向作者/读者索取更多资源

In this study, a facile and biocompatible nanodrug PFD@MPDA-FAPI was developed for targeted drug delivery in pulmonary fibrosis therapy, which showed good antifibrosis properties.
Recently, fibroblast activation protein (FAP), an overexpressed transmembrane protein of activated fibroblast in pulmonary fibrosis, has been considered as the new target for diagnosing and treating pulmonary fibrosis. In this work, mesoporous polydopamine (MPDA), which is facile prepared and easily modified, is developed as a carrier to load antifibrosis drug pirfenidone (PFD) and linking FAP inhibitor (FAPI) to realize lesion-targeted drug delivery for pulmonary fibrosis therapy. We have found that PFD@MPDA-FAPI is well biocompatible and with good properties of antifibrosis, when ICG labels MPDA-FAPI, the accumulation of the nanodrug at the fibrosis lung in vivo can be observed by NIR imaging, and the antifibrosis properties of PFD@MPDA-FAPI in vivo were also better than those of pure PFD and PFD@MPDA; therefore, the easily produced and biocompatible nanodrug PFD@MPDA-FAPI developed in this study is promising for further clinical translations in pulmonary fibrosis antifibrosis therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据